Nafarelin in the Treatment of Endometriosis

article OA: bronze CC0 ⤵ 8 in-corpus citations
AI-generated summary by gemini-2.5-flash-lite, 2026-06-07

Nafarelin, a GnRH agonist, effectively treats endometriosis, with side effects manageable by monitoring estrogen status and adjusting the standard 200 mcg bid intranasal dosage.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Nafarelin, a gonadotropin-releasing hormone agonist, has been shown to be effective in the treatment of endometriosis. The standard dosage is 200 micrograms bid intranasally. Side effects most commonly include those associated with estrogen deprivation. By assessing estrogen status, the standard dosage can be manipulated to minimize these side effects and increase patient compliance.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Nafarelin Administration, Intranasal Adult Analgesia Endometriosis Endometriosis Estradiol Estradiol Female Humans Nafarelin Nafarelin Nafarelin Pelvic Pain Uterine Hemorrhage

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (3)

Cited by (8)

Source provenance

europepmc
last seen: 2026-09-05T06:14:40.014199+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:29.222973+00:00
License: CC0 · commercial use OK